Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Liabilities and Shareholders Equity (2018 - 2025)

TransMedics has reported Liabilities and Shareholders Equity over the past 8 years, most recently at $1.1 billion for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $1.1 billion for Q4 2025, up 32.87% from a year ago — trailing twelve months through Dec 2025 was $3.7 billion (up 21.82% YoY), and the annual figure for FY2025 was $1.1 billion, up 32.87%.
  • Liabilities and Shareholders Equity for Q4 2025 was $1.1 billion at TransMedics, up from $946.0 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for TMDX hit a ceiling of $1.1 billion in Q4 2025 and a floor of $117.3 million in Q2 2022.
  • Median Liabilities and Shareholders Equity over the past 5 years was $689.8 million (2023), compared with a mean of $526.6 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: dropped 17.68% in 2021 and later surged 488.62% in 2023.
  • TransMedics' Liabilities and Shareholders Equity stood at $134.9 million in 2021, then surged by 105.46% to $277.1 million in 2022, then skyrocketed by 154.76% to $706.0 million in 2023, then grew by 13.88% to $804.1 million in 2024, then soared by 32.87% to $1.1 billion in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $1.1 billion (Q4 2025), $946.0 million (Q3 2025), and $890.5 million (Q2 2025) per Business Quant data.